homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

April 24, 2020

Myosana Therapeutics

CureDuchenne Ventures raised up to $1 million in seed financing for Seattle startup biotech Myosana Therapeutics. Myosana will use the money to advance development of its technology for non-viral gene delivery targeting Duchenne muscular dystrophy. The company was founded in 2018 by University of Washington School of Medicine faculty members Nick Whitehead and Stan Froehner. As part of the seed funding deal, CureDuchenne CEO and founder Debra Miller will join Myosana's board. Newport Beach, California-based CureDuchenne focuses on research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy.




Email or user name:
Password:
 
Forgot password? Click here.